Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Conclusions
Anti-Remicade antibodies in patients with IBD recognise and functionally inhibit Remsima to a similar degree, suggesting similar immunogenicity and shared immunodominant epitopes on these two infliximab agents. In contrast, anti-adalimumab antibodies do not cross-react with Remsima or Remicade.

Source: Gut - June 2, 2016 Category: Gastroenterology Authors: Ben-Horin, S., Yavzori, M., Benhar, I., Fudim, E., Picard, O., Ungar, B., Lee, S., Kim, S., Eliakim, R., Chowers, Y. Tags: Inflammatory bowel disease Source Type: research